Wednesday, September 7th, 1:00PM EDT

Managing Direct Oral Anticoagulant Inhibitor to Heparin Conversion; Heparin Anti-Xa assay or aPTT?

Sponsored by: Diagnostica Stago, Inc.
C.E. Credits: P.A.C.E. CE Florida CE

Managing Direct Oral Anticoagulant Inhibitor to Heparin Conversion; Heparin Anti-Xa assay or aPTT?

Ever since the introduction of the direct oral anticoagulants (DOACs), such as apixaban and rivaroxaban, laboratory staff and clinicians have been confronted with unique challenges in determining optimal practices when transitions to heparin infusions are needed for patients at high risk of thrombosis. Heparin infusions are commonly needed for patient on DOACs who are admitted to the acute care setting, yet little guidance has been provided on how to manage these transitions. Due to these challenges, clinicians and their laboratory partners have been developing optimal processes to manage these transitions. Recently, a comprehensive practice guideline was published on how to manage these transitions along with an assessment of its performance versus an alternative strategy. This will be discussed in detail, and examples will be provided in using that guideline to manage care.

Learning Objectives
  • Describe the unique challenges transitioning a patient from a direct oral anticoagulant to a heparin infusion
  • Compare and contrast heparin anti-Xa assay levels to aPTT to manage heparin infusions
  • Evaluate recent literature developments on how to manage DOAC to heparin transitions
  • Present a patient on a DOAC transitioning to heparin, appropriately interpret laboratory values to appropriately manage the transition
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.  CE credits are available for this webinar up to 2 years from the date of the live broadcast.

You May Also Like
Loading Comments...